PharmaCorp, which manufactures the drug Aidistan, claims that Aidistan

Question

PharmaCorp, which manufactures the drug Aidistan, claims that Aidistan is more effective than the drug Betatol in treating Puma Syndrome. To support its claim, PharmaCorp cites the fact that one of every two victims of Puma Syndrome is treated successfully with Aidistan alone, as opposed to one out of every three treated with Betatol alone. However, PharmaCorp’s claim cannot be taken seriously in light of the fact that the presence of Gregg’s Syndrome has been known to render Puma Syndrome more resistant to any treatment.

Which of the following, if true, would most support the allegation that PharmaCorp’s claim cannot be taken seriously?

(A) Among people who suffer from both Puma Syndrome and Gregg’s Syndrome, fewer are treated with Aidistan than with Betatol.

(B) Among people who suffer from both Puma Syndrome and Gregg’s Syndrome, fewer are treated with Betatol than with Aidistan.

(C) Gregg’s Syndrome reduces Aidistan’s effectiveness in treating Puma Syndrome more than Betatol’s effectiveness in treating the same syndrome.

(D) Betatol is less effective than Aidistan in treating Gregg’s Syndrome.

(E) Neither Aidistan nor Betatol is effective in treating Gregg’s Syndrome.

Source:  Master GMAT

GMAT0010 · Answer

SajjadAhmad Hi, Could you please explain the logic behind A ? I chose E instead

Piyush27 · Answer

Kindly provide an explanation for the OA.

Posted from my mobile device

Sajjad1994 · Answer

Official Explanation

This argument relies on the assumption that Gregg’s Syndrome is more prevalent among Puma Syndrome victims who take Betatol than among those who take Aidistan.  Choice (A)  essentially affirms this assumption, although it expresses it in a somewhat different way. Given that Gregg’s Syndrome renders any Puma Syndrome treatment less effective, if victims who have both syndromes are treated with Betatol while victims who have only Puma Syndrome are treated with Aidistan, then Aidistan will appear to be more effective, although the absence of Gregg’s Syndrome might in fact be the key factor that explains the differing results.

The correct answer is (A).

vineethshankar · Answer

Hi Sajjad, I always get your questions wrong.. Why is that??

vishumangal · Answer

Because the quested posted or not up to the level of GMAT standards. Many of the posted questions are from unrecognized sources. Try to solve question from recognized sources such as Manhattan and OG.

elavendan1 · Answer

I have few clarifications here:
1. You state the Assumption as following: 
 This argument relies on the assumption that Gregg’s Syndrome is more prevalent among Puma Syndrome victims who take Betatol than among those who take Aidistan. 
My understanding of the question stem: 
Premise 1: PharmaCorp (PC) claims its drug A is more effective in treating Puma Syndrome than is drug B. 
Premise 2: PC states a Stats fact --> 1/2 successful cases for drug A whereas 1/3 such cases for drug B. Both used alone. 
Premise 3: Gregg's Syndrome has been known to render PS more resistant to any treatment. 
Conclusion: PC's claims cannot be taken seriously. 
Nowhere in the Question stem mentioned implicitly that Gregg's syndrome is more prevalent among Puma Syndrome victims,  who take Betatol

2. Rest of the explanation aligns more with C than with A. C states that Gregg's syndrome is indeed a factor, and that nullifies the effect of A more than effect of B. So in the presence of Gregg's Syndrome, PC cannot claim that its drug A is better than B. Though somewhat murkier, option C could not be eliminated.

On the other hand, option A neither supports nor weakens the conclusion. It states that for people with both GS and PS, fewer are treated with A than with B. Question stem states it renders any drug ineffective. So does the #people treated matters? Of course, we can assume that it is because drug A is less effective when both syndromes are present. But that's what option C says.

Can you help me where I am going wrong?

PharmaCorp, which manufactures the drug Aidistan, claims that Aidistan

Prep Toolkit

Top 5 GMAT Debrief Videos

615 to 715 in 15 Days (Ria's Strategies)

More than Quant/Verbal Abilities: Speed vs. Accuracy

745 with Only Self-Prep and GMAT Club

From 555 to 765: 210-point Improvement

Perfect 805 Score Debrief by Julia

My Rewards

GMAT Critical Reasoning (CR) Questions

PharmaCorp, which manufactures the drug Aidistan, claims that Aidistan

Prep Toolkit

615 to 715 in 15 Days (Ria's Strategies)

More than Quant/Verbal Abilities: Speed vs. Accuracy

745 with Only Self-Prep and GMAT Club

From 555 to 765: 210-point Improvement

Perfect 805 Score Debrief by Julia

My Rewards